The primary market is set for a busy stretch next week, with Wakefit Innovations and Corona Remedies launching their initial public offerings on December 8, 2025, and NephroPlus’ on December 10, 2025. These companies have announced their price bands, issue structures, and fundraising plans. Grey-market buzz for Wakefit and Corona Remedies’ suggests healthy investor appetite ahead of subscription openings.

Key details of Corona Remedies IPO

Pharma company Corona Remedies, backed by private equity firm ChrysCapital, has fixed a price band of ₹1,008–1,062 per share, valuing the business at nearly ₹6,500 crore.

Its ₹655.37 crore issue is entirely an offer for sale (OFS) by promoters and existing investors, including Sepia Investments, Anchor Partners and Sage Investment Trust. Since the IPO

See Full Page